Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Predictive value of combined analysis of pro-NPY and ERG in localized prostate cancer

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{e68a30466f194403b9c2f7722179e113,
title = "Predictive value of combined analysis of pro-NPY and ERG in localized prostate cancer",
abstract = "This study aimed to investigate if combined analysis of pro-Neuropeptide Y (NPY) and ERG expression in tumor tissue are associated with biochemical failure (BF), castration-based treatment, castration-resistant prostate cancer (CRPC), and prostate cancer (PCa)-specific death for men undergoing radical prostatectomy (RP) for PCa. This study included 315 patients, who underwent RP from 2002 to 2005. Both pro-NPY and ERG expression were analyzed using immunohistochemistry and were scored as low or high and negative or positive, respectively. Risk of BF, castration-based treatment, CRPC, and PCa-specific death were analyzed with multiple cause-specific Cox regression analyses and stratified cumulative incidences using competing risk assessment. Median follow-up was 13.0 years (95{\%} CI: 12.7-13.2). In total, 85.7{\%} were pro-NPY high and 14.3{\%} were pro-NPY low. The combined analyses of pro-NPY and ERG expression was not associated with risk of BF (p = 0.7), castration-based treatment (p = 0.8), CRPC (p = 0.4) or PCa-specific death (p = 0.5). In the multiple cause-specific Cox regression analysis, pro-NPY high and ERG positivity was not associated with BF (HR: 1.02; 95{\%} CI 0.6-1.7; p = 0.94). In conclusion the combination of pro-NPY and ERG expression did not show association with risk of BF, castration-based treatment, CRPC, and PCa-specific death following RP.",
author = "Gitte Kristensen and R{\o}der, {Martin Andreas} and Berg, {Kasper Drimer} and Johanna Elversang and Diego Iglesias-Gato and Jos{\'e} Moreira and Toft, {Birgitte Gr{\o}nk{\ae}r} and Klaus Brasso",
note = "{\circledC} 2018 APMIS. Published by John Wiley & Sons Ltd.",
year = "2018",
month = "10",
doi = "10.1111/apm.12886",
language = "English",
volume = "126",
pages = "804--813",
journal = "APMIS - Journal of Pathology, Microbiology and Immunology",
issn = "0903-4641",
publisher = "Wiley Online",
number = "10",

}

RIS

TY - JOUR

T1 - Predictive value of combined analysis of pro-NPY and ERG in localized prostate cancer

AU - Kristensen, Gitte

AU - Røder, Martin Andreas

AU - Berg, Kasper Drimer

AU - Elversang, Johanna

AU - Iglesias-Gato, Diego

AU - Moreira, José

AU - Toft, Birgitte Grønkær

AU - Brasso, Klaus

N1 - © 2018 APMIS. Published by John Wiley & Sons Ltd.

PY - 2018/10

Y1 - 2018/10

N2 - This study aimed to investigate if combined analysis of pro-Neuropeptide Y (NPY) and ERG expression in tumor tissue are associated with biochemical failure (BF), castration-based treatment, castration-resistant prostate cancer (CRPC), and prostate cancer (PCa)-specific death for men undergoing radical prostatectomy (RP) for PCa. This study included 315 patients, who underwent RP from 2002 to 2005. Both pro-NPY and ERG expression were analyzed using immunohistochemistry and were scored as low or high and negative or positive, respectively. Risk of BF, castration-based treatment, CRPC, and PCa-specific death were analyzed with multiple cause-specific Cox regression analyses and stratified cumulative incidences using competing risk assessment. Median follow-up was 13.0 years (95% CI: 12.7-13.2). In total, 85.7% were pro-NPY high and 14.3% were pro-NPY low. The combined analyses of pro-NPY and ERG expression was not associated with risk of BF (p = 0.7), castration-based treatment (p = 0.8), CRPC (p = 0.4) or PCa-specific death (p = 0.5). In the multiple cause-specific Cox regression analysis, pro-NPY high and ERG positivity was not associated with BF (HR: 1.02; 95% CI 0.6-1.7; p = 0.94). In conclusion the combination of pro-NPY and ERG expression did not show association with risk of BF, castration-based treatment, CRPC, and PCa-specific death following RP.

AB - This study aimed to investigate if combined analysis of pro-Neuropeptide Y (NPY) and ERG expression in tumor tissue are associated with biochemical failure (BF), castration-based treatment, castration-resistant prostate cancer (CRPC), and prostate cancer (PCa)-specific death for men undergoing radical prostatectomy (RP) for PCa. This study included 315 patients, who underwent RP from 2002 to 2005. Both pro-NPY and ERG expression were analyzed using immunohistochemistry and were scored as low or high and negative or positive, respectively. Risk of BF, castration-based treatment, CRPC, and PCa-specific death were analyzed with multiple cause-specific Cox regression analyses and stratified cumulative incidences using competing risk assessment. Median follow-up was 13.0 years (95% CI: 12.7-13.2). In total, 85.7% were pro-NPY high and 14.3% were pro-NPY low. The combined analyses of pro-NPY and ERG expression was not associated with risk of BF (p = 0.7), castration-based treatment (p = 0.8), CRPC (p = 0.4) or PCa-specific death (p = 0.5). In the multiple cause-specific Cox regression analysis, pro-NPY high and ERG positivity was not associated with BF (HR: 1.02; 95% CI 0.6-1.7; p = 0.94). In conclusion the combination of pro-NPY and ERG expression did not show association with risk of BF, castration-based treatment, CRPC, and PCa-specific death following RP.

U2 - 10.1111/apm.12886

DO - 10.1111/apm.12886

M3 - Journal article

VL - 126

SP - 804

EP - 813

JO - APMIS - Journal of Pathology, Microbiology and Immunology

JF - APMIS - Journal of Pathology, Microbiology and Immunology

SN - 0903-4641

IS - 10

ER -

ID: 55350213